None listed
Conditions
Brief summary
This study will determine the effect of resveratrol - a plant derived polyphenol - on blood clot formation in patients undergoing liver resection for cancers Who is it for? You may be eligible to join this study if you are aged 18 years old or above and have colonic cancer secondary to the liver or cholangiocarcinoma requiring liver resection Study details Participants in this study are randomly allocated (by chance) to one of two groups. Participants in one group will receive resveratrol capsules (2 capsules with a total of resveratrol 1g/day) in the morning daily for 7 days before surgery, whilst participants in the other group will receive a placebo (2 capsules of fine sugar ~1g/day) in the morning daily for 7 days before surgery. Blood taken from participants before and after surgery will be used to analyse blood clot formation in participants. The proposed study is an essential step before a larger confirmatory phase II clinical study including important patient-centred outcomes can be initiated. A larger phase II study will provide the much needed information about the benefits and harms of using resveratrol in major cancer surgery.
Interventions
Oral resveratrol (1g/day) or placebo capsules for 7 days before liver resection for cancer. Study drug compliance will be confirmed with the patients on the day of surgery.
Sponsors
Kwok Ming Ho
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Colonic cancer secondary to the liver or cholangiocarcinoma requiring liver resection.
Exclusion criteria
Patients with known coagulation abnormality, treated with systemic anticoagulants, taking resveratrol as part of their usual supplements before enrolment, and pregnant patients.
Outcome results
None listed